BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
Want to see BBOT full AI Analyst Report?
Top Page
BridgeBio Oncology Therapeutics
(NASDAQ:BBOT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$8.00
▼(-36.46% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by pre-revenue financial performance with widening losses and substantial cash burn, alongside a bearish technical setup (price below key moving averages and negative MACD). A low-debt balance sheet provides some support, and the leadership changes are a modest positive, but valuation remains constrained by ongoing losses and no dividend.
Positive Factors
Low leverage / solid balance sheet
Very low debt (debt-to-equity ~0.7%) and sizable equity provide durable financial flexibility to fund R&D and clinical programs without excessive interest burden. This reduces bankruptcy risk and supports multi-stage clinical development timelines despite ongoing losses.
Negative Factors
Pre-revenue with widening net losses
The company remains pre-revenue with escalating net losses (from -$64.7M in 2023 to -$154.1M TTM). Without product revenue, ongoing losses are structural, limiting internal funding capacity and increasing reliance on external capital to sustain clinical programs over multiple years.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / solid balance sheet
Very low debt (debt-to-equity ~0.7%) and sizable equity provide durable financial flexibility to fund R&D and clinical programs without excessive interest burden. This reduces bankruptcy risk and supports multi-stage clinical development timelines despite ongoing losses.
Read all positive factors
BridgeBio Oncology Therapeutics (BBOT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$705.74M
Dividend YieldN/A
Average Volume (3M)344.97K
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue GrowthN/A
EPS Growth-206431.48%
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding80,107,100
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.53K
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$24.06Price Target Upside91.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BridgeBio Oncology Therapeutics Business Overview & Revenue Model
Company Description
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidi...
How the Company Makes Money
BridgeBio Oncology Therapeutics generates revenue primarily through the commercialization of its oncology drug portfolio, once they are approved by regulatory agencies. Additional revenue streams may include licensing agreements, partnerships with...
BridgeBio Oncology Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -186.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -168.12M | -145.21M | -80.66M | -64.68M | -3.52K | -43.36K |
| Net Income | -154.09M | -134.04M | -74.28M | -64.70M | -3.52K | -43.36K |
Balance Sheet | ||||||
| Total Assets | 417.65M | 448.38M | 194.42M | 332.89K | 144.58K | 144.28K |
| Cash, Cash Equivalents and Short-Term Investments | 252.28M | 425.46M | 1.70M | 0.00 | 0.00 | 0.00 |
| Total Debt | 2.64M | 2.77M | 0.00 | 70.09K | 43.11K | 36.96K |
| Total Liabilities | 45.37M | 37.28M | 5.71M | 396.46K | 166.46K | 162.64K |
| Stockholders Equity | 372.28M | 411.10M | 188.72M | -63.57K | -21.88K | -18.36K |
Cash Flow | ||||||
| Free Cash Flow | -172.93M | -114.50M | -763.82K | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow | -172.07M | -113.89M | -763.82K | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | -202.44M | 73.33M | -184.00M | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 402.65M | 383.40M | 186.46M | 0.00 | 0.00 | 0.00 |
BridgeBio Oncology Therapeutics Risk Analysis
BridgeBio Oncology Therapeutics disclosed 94 risk factors in its most recent earnings report. BridgeBio Oncology Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BridgeBio Oncology Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
BBOT
BridgeBio Oncology Therapeutics
8.81
-2.01
-18.58%
FORL
Four Leaf Acquisition Corporation Class A
11.00
-0.41
-3.59%
QETA
Quetta Acquisition Corp.
12.02
1.33
12.49%
BridgeBio Oncology Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
BridgeBio Oncology Overhauls Leadership for Next Development Phase
Positive
Apr 23, 2026
On April 22, 2026, BridgeBio Oncology Therapeutics announced a leadership overhaul effective April 20, 2026, appointing former Chief Scientific Officer Pedro J. Beltran, PhD, as Chief Executive Officer and elevating former Senior Vice President of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.